A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer

Abstract Background We developed and refined an S-1 dosage formula based on renal function, sex, and body surface area (BSA) to achieve the target area under the concentration–time curve of 5-fluorouracil in two prospective pharmacokinetic studies. The clinical validity of the refined formula (BBT f...

全面介紹

書目詳細資料

發表在:	BMC Cancer
Main Authors:	Keisuke Baba, Nobumi Suzuki, Chiyo K. Imamura, Eisuke Booka, Masashi Takeuchi, Daisuke Takahari, Takeshi Kawakami, Hirofumi Kawakubo, Chiyoe Kitagawa, Yoshiyasu Kono, Keiji Ogura, Yosuke Kito, Kei Saito, Shinzo Yamamoto, Hiroya Takeuchi, Toshihiro Kudo, Takuya Tsunoda, Takuro Mizukami, Toshifumi Yamaguchi, Hirokazu Shoji, Kanako Saito, Kenro Tanoue, Eishi Baba, Kengo Nagashima, Narikazu Boku
格式:	Article
語言:	英语
出版:	BMC 2025-04-01
主題:	Advanced gastric cancer Dosage formula Nivolumab S- 1 Oxaliplatin
在線閱讀:	https://doi.org/10.1186/s12885-025-14084-1